secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001501697-25-000041
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma Q3 net loss $29.8M ($0.69/sh); cash runway to end 2028 after $240.3M financing
--------------------------------------------------------------------------------

- Q3 net product sales XOLREMDI $1.6M vs $0.6M YoY; net loss $0.69/sh vs $5.48/sh in Q3 2024.
- Raised $240.3M gross via public offering and upsized private placement; cash runway extended to end of 2028.
- 50% workforce reduction yields ~$13M annualized cost savings; focus on Phase 3 4WARD chronic neutropenia trial.
- Enrollment target for 4WARD increased to 176 patients; expected completion Q3 2026; sNDA potential in chronic neutropenia.
- Deprioritized XOLREMDI commercialization for WHIM syndrome; John Volpone promoted to COO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/0001501697-25-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000150169725000041/xfor-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001501697-25-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer